RECENT PUBLICATIONS 

Click on article title to read

2022

Exhausted T cell phenotypes depend on TCR signal strength.Tran MA, Bhardwaj N. Nature Reviews Immunology 2022. PMID:35194170

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trialMarron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Lancet Gastroenterology+Hepatology 2022. PMID: 35065058

2021

New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapyGreene E, Finak G, D’Amico LA, Bhardwaj N, Church CD, Morishima C, Ramchurren N, Taube JM, Nghiem PT, Cheever MA, Fling SP, Gottardo R. Patterns 2021. PMID: 34950900

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myelomaAleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K; PVI/Seronet Study Group, Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Cancer Cell 2021. PMID: 34706273
Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines. Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N. Frontiers in Immunology. PMID: 34630437
PD-1 inhibition in advanced myeloproliferative neoplasmsHobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster JE, Som T, Macrae M, Marble H, Salama M, El Jamal SM, Zubizarreta N, Wadleigh M, Stone R, Bhardwaj N, Iancu-Rubin C, Mascarenhas J. Blood Advances 2021. PMID: 34581778
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. Cimen Bozkus C, Bhardwaj N. Cancer Cell 2021. PMID: 34478641
A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. Cimen Bozkus C, Blazquez AB, Enokida T, Bhardwaj N. STAR Protocols 2021. PMID: 34458873
Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFsWeingarten-Gabbay S, Klaeger S, Sarkizova S, Pearlman LR, Chen DY, Gallagher KME, Bauer MR, Taylor HB, Dunn WA, Tarr C, Sidney J, Rachimi S, Conway HL, Katsis K, Wang Y, Leistritz-Edwards D, Durkin MR, Tomkins-Tinch CH, Finkel Y, Nachshon A, Gentili M, Rivera KD, Carulli IP, Chea VA, Chandrashekar A, Bozkus CC, Carrington M; MGH COVID-19 Collection & Processing Team, Bhardwaj N, Barouch DH, Sette A, Maus MV, Rice CM, Clauser KR, Keskin DB, Pregibon DC, Hacohen N, Carr SA, Abelin JG, Saeed M, Sabeti PC. Cell. 2021. PMID: 34171305

Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. Sfakianos JP, Salome B, Daza J, Farkas A, Bhardwaj N, Horowitz A. Urologic Oncology 2021. PMID: 33262028

MMP2 and TLRs modulate immune responses in the tumor microenvironment. Muniz-Bongers LR, McClain CB, Saxena M, Bongers G, Merad M, Bhardwaj N. JCI Insight. 2021. PMID: 34032639

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. Clin Cancer Res. 2021. PMID: 33837006

Uncloaking Breast Tumor Neoantigens with Radiation. Newman JH, Bhardwaj N. Trends Immunol. 2021.PMID: 33674225

Super(antigen) target for SARS-CoV-2.  Brown M, Bhardwaj N. Nat Rev Immunol. 2021. PMID: 33432128 

2020

Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O’Donnell T, Chakraborty L, Samstein R, Huang KL, Blank SV, Greenbaum B, Bhardwaj N. Cell. 2020.

Unexplored horizons of cDC1 in immunity and tolerance. Balan S, Radford KJ, Bhardwaj N. Adv Immunol. 2020.

TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. Attalla K, Farkas AM, Anastos H, Audenet F, Galsky MD, Bhardwaj N, Sfakianos JP. Urol Oncol. 2020.

Cross-Presentation of Tumor Antigens Is Ruled by Synaptic Transfer of Vesicles among Dendritic Cell Subsets. Balan S, Bhardwaj N. Cancer Cell. 2020.

A conserved dendritic-cell regulatory program limits antitumour immunity.Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, Chudnovskiy A, Maskey S, Walker L, Finnigan JP, Kirkling ME, Reizis B, Ghosh S, D’Amore NR, Bhardwaj N, Rothlin CV, Wolf A, Flores R, Marron T, Rahman AH, Kenigsberg E, Brown BD, Merad M. Nature 2020.

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S. Clin Cancer Res. 2020.

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj NCancer Immunol Res. 2020.

 

————————————————————————————

FOR A LIST OF ALL PUBLICATIONS – CLICK HERE

————————————————————————————